Novel Design of (PEG-ylated)PAMAM-based Nanoparticles for Sustained Delivery of BDNF to Neurotoxin-injured Differentiated Neuroblastoma Cells

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2020 Sep 2

PMID 32867843

Citations 13

Authors

Maria Dabkowska

Karolina Luczkowska

Dorota Roginska

Anna Sobus

Monika Wasilewska

Zofia Ulanczyk

Boguslaw Machalinski

Affiliations

Soon will be listed here.

Abstract

Brain-derived neurotrophic factor (BDNF) is essential for the development and function of human neurons, therefore it is a promising target for neurodegenerative disorders treatment. Here, we studied BDNF-based electrostatic complex with dendrimer nanoparticles encapsulated in polyethylene glycol (PEG) in neurotoxin-treated, differentiated neuroblastoma SH-SY5Y cells, a model of neurodegenerative mechanisms. PEG layer was adsorbed at dendrimer-protein core nanoparticles to decrease their cellular uptake and to reduce BDNF-other proteins interactions for a prolonged time. Cytotoxicity and confocal microscopy analysis revealed PEG-ylated BDNF-dendrimer nanoparticles can be used for continuous neurotrophic factor delivery to the neurotoxin-treated cells over 24 h without toxic effect. We offer a reliable electrostatic route for efficient encapsulation and controlled transport of fragile therapeutic proteins without any covalent cross-linker; this could be considered as a safe drug delivery system. Understanding the polyvalent BDNF interactions with dendrimer core nanoparticles offers new possibilities for design of well-ordered protein drug delivery systems.

Citing Articles

Impact and Mechanisms of Action of BDNF on Neurological Disorders, Cancer, and Cardiovascular Diseases.

Lei M, Liu Q, Nie J, Huang R, Mei Y, Pan D CNS Neurosci Ther. 2024; 30(12):e70138.

PMID: 39648800 PMC: 11626086. DOI: 10.1111/cns.70138.

Bioactivities and Anti-Cancer Activities of NKT-Stimulatory Phenyl-Glycolipid Formulated with a PEGylated Lipid Nanocarrier.

Hung J, Chiou S, Tang Y, Huang J, Lo F, Yu A Drug Des Devel Ther. 2024; 18:5323-5332.

PMID: 39583633 PMC: 11586003. DOI: 10.2147/DDDT.S484130.

BDNF-loaded PDADMAC-heparin multilayers: a novel approach for neuroblastoma cell study.

Dabkowska M, Stukan I, Kowalski B, Donerowicz W, Wasilewska M, Szatanik A Sci Rep. 2023; 13(1):17939.

PMID: 37864014 PMC: 10589271. DOI: 10.1038/s41598-023-45045-y.

The Impact of Serum Protein Adsorption on PEGylated NT3-BDNF Nanoparticles-Distribution, Protein Release, and Cytotoxicity in a Human Retinal Pigmented Epithelial Cell Model.

Dabkowska M, Kosiorowska A, Machalinski B Pharmaceutics. 2023; 15(9).

PMID: 37765206 PMC: 10537189. DOI: 10.3390/pharmaceutics15092236.

Targeted Bioluminescent Imaging of Pancreatic Ductal Adenocarcinoma Using Nanocarrier-Complexed EGFR-Binding Affibody-Gaussia Luciferase Fusion Protein.

Hersh J, Yang Y, Roberts E, Bilbao D, Tao W, Pollack A Pharmaceutics. 2023; 15(7).

PMID: 37514162 PMC: 10384630. DOI: 10.3390/pharmaceutics15071976.

References

Zhou C, Zhong J, Zou B, Fang L, Chen J, Deng X . Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression. PLoS One. 2017; 12(2):e0172270. PMC: 5328267. DOI: 10.1371/journal.pone.0172270. View

Beal M . Experimental models of Parkinson's disease. Nat Rev Neurosci. 2001; 2(5):325-34. DOI: 10.1038/35072550. View

Giri J, Diallo M, Simpson A, Liu Y, Goddard W, Kumar R . Interactions of poly(amidoamine) dendrimers with human serum albumin: binding constants and mechanisms. ACS Nano. 2011; 5(5):3456-68. DOI: 10.1021/nn1021007. View

Cao J, Ge R, Zhang M, Xia J, Han S, Lu W . A triple modality BSA-coated dendritic nanoplatform for NIR imaging, enhanced tumor penetration and anticancer therapy. Nanoscale. 2018; 10(19):9021-9037. DOI: 10.1039/c7nr09552j. View

. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999; 52(7):1427-33. DOI: 10.1212/wnl.52.7.1427. View

Tome D, Fonseca C, Campos F, Baltazar G . Role of Neurotrophic Factors in Parkinson's Disease. Curr Pharm Des. 2016; 23(5):809-838. DOI: 10.2174/1381612822666161208120422. View

Domenech R, Abian O, Bocanegra R, Correa J, Sousa-Herves A, Riguera R . Dendrimers as potential inhibitors of the dimerization of the capsid protein of HIV-1. Biomacromolecules. 2010; 11(8):2069-78. DOI: 10.1021/bm100432x. View

Ghadami S, Chia S, Ruggeri F, Meisl G, Bemporad F, Habchi J . Transthyretin Inhibits Primary and Secondary Nucleations of Amyloid-β Peptide Aggregation and Reduces the Toxicity of Its Oligomers. Biomacromolecules. 2020; 21(3):1112-1125. PMC: 7997117. DOI: 10.1021/acs.biomac.9b01475. View

Faridi A, Yang W, Kelly H, Wang C, Faridi P, Purcell A . Differential Roles of Plasma Protein Corona on Immune Cell Association and Cytokine Secretion of Oligomeric and Fibrillar Beta-Amyloid. Biomacromolecules. 2019; 20(11):4208-4217. PMC: 9285861. DOI: 10.1021/acs.biomac.9b01116. View

10.

Curtis R, Ulrich J, Montaser A, Prausnitz J, Blanch H . Protein-protein interactions in concentrated electrolyte solutions. Biotechnol Bioeng. 2002; 79(4):367-80. DOI: 10.1002/bit.10342. View

11.

Geral C, Angelova A, Lesieur S . From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics. 2013; 5(1):127-67. PMC: 3834942. DOI: 10.3390/pharmaceutics5010127. View

12.

Chao M . Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003; 4(4):299-309. DOI: 10.1038/nrn1078. View

13.

Dravid A, Parittotokkaporn S, Aqrawe Z, OCarroll S, Svirskis D . Determining Neurotrophin Gradients in Vitro To Direct Axonal Outgrowth Following Spinal Cord Injury. ACS Chem Neurosci. 2019; 11(2):121-132. DOI: 10.1021/acschemneuro.9b00565. View

14.

Lopes C, Goncalves N, Gomes C, Saraiva M, Pego A . BDNF gene delivery mediated by neuron-targeted nanoparticles is neuroprotective in peripheral nerve injury. Biomaterials. 2017; 121:83-96. DOI: 10.1016/j.biomaterials.2016.12.025. View

15.

Li J, Zhang X, Tang X, Xiao W, Ye F, Sha W . Neurotrophic factor changes are essential for predict electroconvulsive therapy outcome in schizophrenia. Schizophr Res. 2020; 218:295-297. DOI: 10.1016/j.schres.2019.10.035. View

16.

Fahrlander E, Schelhaas S, Jacobs A, Langer K . PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. Nanotechnology. 2015; 26(14):145103. DOI: 10.1088/0957-4484/26/14/145103. View

17.

Ma W, Fu F, Zhu J, Huang R, Zhu Y, Liu Z . Cu-Labeled multifunctional dendrimers for targeted tumor PET imaging. Nanoscale. 2018; 10(13):6113-6124. PMC: 7473786. DOI: 10.1039/C7NR09269E. View

18.

Dabkowska M, Roginska D, Klos P, Sobus A, Adamczak M, Litwinska Z . Electrostatic complex of neurotrophin 4 with dendrimer nanoparticles: controlled release of protein in vitro and in vivo. Int J Nanomedicine. 2019; 14:6117-6131. PMC: 6682179. DOI: 10.2147/IJN.S210140. View

19.

Parimi S, Barnes T, Callen D, Prestidge C . Mechanistic insight into cell growth, internalization, and cytotoxicity of PAMAM dendrimers. Biomacromolecules. 2009; 11(2):382-9. DOI: 10.1021/bm9010134. View

20.

Xicoy H, Wieringa B, Martens G . The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017; 12(1):10. PMC: 5259880. DOI: 10.1186/s13024-017-0149-0. View